We are delighted to announce that Dr James Pickett has been appointed as Epilepsy Research UK’s first ever Director of Research & Innovation.

A collaborative leader

James will join ERUK after 10 years with the Alzheimer’s Society, where he was instrumental in growing the dementia research programme in basic, clinical and social research. James created many new national and international research partnerships and collaborations that spanned academia, government funding, industry and people affected by dementia. During this time the charity and the UK government have tripled the financial investment in dementia research.

James has a PhD from the University of Cambridge and has previously worked in journal publishing at Nature and in grant funding at Diabetes UK. He was recently selected as a Future Leader in Innovation, Enterprise and Research (FLIER) Fellow by the Academy of Medical Science; an award founded to develop interdisciplinary leaders of life sciences.

In his own words

James said: “Research is my passion. I am thrilled to be joining Epilepsy Research UK at a pivotal time in the charity’s development.

“I look forward to working with researchers, doctors and people living with epilepsy to set out our bold research strategy to make sure we deliver research that improves lives. In the first few months I will be getting out and about as much as I can, and I can’t wait to meet everyone and discuss ideas for moving research into epilepsy forward.”

A warm welcome from the ERUK Chair of Trustees & CEO

Professor Matthew Walker said: “It is an incredibly exciting time in neuroscience. There are many emerging tools and technologies which can be applied to study the brain, and new ideas about types of treatments and therapies. I’m delighted James is joining Epilepsy Research UK to drive forward our research and make sure people with epilepsy don’t miss out on the research breakthroughs of the future.”

ERUK Chief Executive, Maxine Smeaton says, “With James’ leadership, expertise and proven track record in forging vital partnerships, ERUK are in a better position than ever to drive investment in research and develop our programme of life changing, life saving research into epilepsy.”